Advertisement

Picture Berlin Partner Top News Aignostics $43m AI Precision Medicine 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 958 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Kivu Bioscience–Novo Group: investment, 202410 financing round Series A totalling $92m incl lead investor Novo Holdings 2024-10-28
Kivu Bioscience–Odlander Fredrikson: investment, 202410 financing round Series A totalling $92m incl new + co-investor HealthCap 2024-10-28
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings 2024-10-28
Booster Therapeutics–Novo Group: investment, 202410 seed financing round totalling $15m incl co-lead investor Novo Holdings 2024-10-10
Booster Therapeutics–SEVERAL: investment, 202410 seed financing round $15m led by Apollo Health Ventures + Novo Holdings 2024-10-10
Novo Group–Evotec: cell therapy manufacturing, 202409– collab technology development €na RnD funding + upfront + milestone payments plus royalties 2024-09-26
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries 2024-09-16
PanTera–SEVERAL: investment, 202409 financing round Series A €93m led by EQT Life Sciences 2024-09-11
Biomatter Designs–Inventure: investment, 202408 seed financing round totalling €6.5m co-led by Inventure 2024-08-05
Biomatter Designs–SEVERAL: investment, 202408 seed financing round €6.5m led by Inventure + UVC Partners 2024-08-05
Draupnir Bio–ABP (NL): Investment, 202407 seed financing round totalling €12m incl existing investor Inkef Capital 2024-07-17
Draupnir Bio–Denmark (govt): Investment, 202407 seed financing round totalling €12m incl new investor EIFO 2024-07-17
Draupnir Bio–Gilde Investment: Investment, 202407 seed financing round totalling €12m incl existing investor Gilde Healthcare Partners 2024-07-17
Draupnir Bio–Mitsubishi Chemical: Investment, 202407 seed financing round totalling €12m incl new investor MP Healthcare 2024-07-17
Draupnir Bio–Novo Group: Investment, 202407 seed financing round totalling €12m incl existing investor Novo Holdings 2024-07-17
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round €12m with MP Healthcare + EIFO + Gilde HP + Inkef Capital + Novo Holdings 2024-07-17
Asceneuron–EQT: investment, 202407 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences - LSP Dementia Fund 2024-07-16
Asceneuron–Novo Group: investment, 202407 financing round Series C totalling $100m incl lead investor Novo Holdings 2024-07-16
Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings 2024-07-16
HepaRegenix–Novo Group: investment, 202407 financing round Series C totalling €15m incl existing + co-investor Novo Holdings 2024-07-10
HepaRegenix–SEVERAL: investment, 202407 financing round Series C €15m led by Vesalius Biocapital IV 2024-07-10
SciRhom–Hadean Ventures: investment, 202407 financing round Series A totalling €63m incl co-lead investor Hadean Ventures 2024-07-09
SciRhom–SEVERAL: investment, 202407 financing round Series A €63m 2024-07-09
Myricx Pharma–Novo Group: investment, 202407 financing round Seires A totalling £90m incl new + co-lead investor Novo Holidngs 2024-07-08
Myricx Pharma–SEVERAL: investment, 202407 financing round Seires A £90m led by Novo Holidngs + Abingworth 2024-07-08
Sequrna–Genovis: investment, 202407 acquisition of 25% shareholding €na by Genovis with conditional call option until 6/27 to acquire all shares 2024-07-04
Forbion–SEVERAL: investment, 202406 first closing €75m of Forbion BioEconomy Fund I incl KfW Capital + Novo Holdings + Rentenbank 2024-06-20
PINK gegen Brustkrebs–Sidekick Health: investment, 202406 acquisition of PINK! by Sidekick Health 2024-06-18
Novo Group–Hikma: investment, 202406– acquisition $135m upfront + $50m milestones part of Xellia’s business incl Cleveland plant + Zabreg RnD Center 2024-06-17
Moleculent–ARCH Venture: investment, 2020406 financing round Series A totalling $26m incl lead investor ARCH Venture Partners 2024-06-11
Moleculent–Bioscribe: public relations, 202406 service existent by Bioscribe 2024-06-11
Moleculent–Eir Ventures: investment, 2020406 financing round Series A totalling $26m incl co-lead investor Eir Ventures 2024-06-11
Moleculent–OTHER: investment, 2020406 financing round Series A totalling $26m incl existing investors as co-investors 2024-06-11
Moleculent–SEVERAL: investment, 2020406 financing round Series A $26m led by ARCH Venture Partners 2024-06-11
Adcendo–Gilde Investment: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Gilde Healthcare 2024-05-29
Adcendo–KKR: investment, 202405 financing round Series A 2nd extension totalling €16m incl new + lead investor Dawn Biopharma 2024-05-29
Adcendo–Novo Group: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Novo Holdings 2024-05-29
Adcendo–Odlander Fredrikson: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor HealthCap 2024-05-29
Adcendo–Pontifax: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Pontifax Venture Capital 2024-05-29
Adcendo–RA Capital: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor RA Capital Management 2024-05-29
Adcendo–SEVERAL: investment, 202405 financing round Series A 2nd extension €16m bringing total Series A to €96m 2024-05-29
Adcendo–Ysios Capital: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Ysios Capital 2024-05-29
Calliditas Therapeutics–Asahi Kasei: investment, 202405– acquisition cash tender offer SEK11.8b (JPY174b) by Asahi Kasei ANNOUNCED 2024-05-28
Single Use Support–Novo Group: investment, 202405 acquisition of 60% majority share by Novo Holdings 2024-05-15
ArgusEye–Eir Ventures: investment, 202405 financing round totalling €2.8m incl existing + co-lead investor Eir Ventures 2024-05-13
ArgusEye–SEVERAL: investment, 202405 financing round €2.8m led by Voima Ventures + co-led by Eir Ventures 2024-05-13
ArgusEye–Voima Ventures: investment, 202405 financing round totalling €2.8m incl lead investor Voima Ventures 2024-05-13
Bluejay Therapeutics–SEVERAL: investment, 202405 financing round Series C $182m co-led by Frazier LS + undisclosed institutional LS investor 2024-05-09
Commit Biologics–Bioqube Ventures: investment, 202405 seed financing round totalling €16m incl co-lead investor Bioqube Ventures 2024-05-09
Commit Biologics–Novo Group: investment, 202405 seed financing round totalling €16m incl co-lead investor Novo Holdings 2024-05-09
Commit Biologics–SEVERAL: investment, 202405 seed financing round €16m led by Bioqube Ventures + Novo Holdings 2024-05-09
Insempra–EQT: investment, 202405 financing round Series A totalling $20m incl existing investor EQT Ventures 2024-05-07
Insempra–SEVERAL: investment, 202405 financing round Series A $20m with existing + new investors 2024-05-07
Theolytics–SEVERAL: investment, 202404 financing round £19m incl new investor Sound Bioventures 2024-04-17
Theolytics–Sound Bioventures: investment, 202404 financing round totalling £19m incl new investor Sound Bioventures 2024-04-17
ProfoundBio–Genmab: investment, 202403– acqusition $1.8b in cash of ProfoundBio by Genmab ANNOUNCED 2024-04-03
Protembis–SEVERAL: investment, –202403 financing round Series B €30m completed in two separate capital increases 2024-03-26
Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED 2024-03-25
Amolyt Pharma–AstraZeneca: investment, 202403– acquisition $800m upfront cash + $250m milestones 2024-03-14
Asgard Therapeutics–Boehringer: investment, 202403 financing round Series A totalling €30m incl existing + co-investor BIVF 2024-03-14
Asgard Therapeutics–JnJ: investment, 202403 financing round Series A totalling €30m incl co-lead investor JnJ Innovation JJDC 2024-03-14
Asgard Therapeutics–Novo Group: investment, 202403 financing round Series A totalling €30m incl existing + co-investor Novo Holdings 2024-03-14
Asgard Therapeutics–SEVERAL: investment, 202403 financing round Series A €30m co-led by RV Invest + JnJ Innovation 2024-03-14
Asgard Therapeutics–Sweden (govt): investment, 202403 financing round Series A totalling €30m incl existing + co-investor Industrifonden 2024-03-14
Asgard Therapeutics–Vetter: investment, 202403 financing round Series A totalling €30m incl co-lead investor RV Invest 2024-03-14
Tubulis–EQT: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor EQT Life Sciences 2024-03-14
Tubulis–SEVERAL: investment, 202403 financing round Series B2 €128m led by EQT Life Sciences + Nextech Invest 2024-03-14
Commit Biologics–Denmark (govt): grant, 202402 Innobooster Grant DKK5m from Innovation Fund Denmark 2024-02-14
TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces 2024-01-30
Vico Therapeutics–EQT: investment, 202401 financing round Series B totalling €54m incl existing + co-lead investor EQT Life Sciences 2024-01-05
Vico Therapeutics–SEVERAL: investment, 202401 financing round Series B €54m led by new investor Ackermans & van Haaren 2024-01-05
Resalis Therapeutics–Claris Ventures: investment, 202401 financing round Series A totalling €10m incl existing + co-investor Claris Ventures 2024-01-04
Resalis Therapeutics–OTHER: investment, 202401 financing round Series A totalling €10m incl angel investos as existing + co-investors 2024-01-04
Resalis Therapeutics–SEVERAL: investment, 202401 financing round Series A €10m led by new investor Sunstone Life Science Ventures 2024-01-04
Resalis Therapeutics–Sunstone Life Science: investment, 202401 financing round Series A totalling €10m incl new + lead investor Sunstone LSV 2024-01-04
Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ 2023-12-21
Freya Biosciences–Angelini: investment, 202312 financing round Series A totalling $38m incl co-investor Angelini Ventures 2023-12-12
Freya Biosciences–Corundum Systems Biology: investment, 202312 financing round Series A totalling $38m incl co-investor Corundum Systems Biology 2023-12-12
Freya Biosciences–Crescent Enterprises: investment, 202312 financing round Series A totalling $38m incl co-investor CE-Ventures 2023-12-12
Freya Biosciences–Denmark (govt): investment, 202312 financing round Series A totalling $38m incl co-investor EIFO 2023-12-12
Freya Biosciences–Indaco Venture: investment, 202312 financing round Series A totalling $38m incl co-investor Indaco Venture Partners 2023-12-12
Freya Biosciences–OMX Ventures: investment, 202312 financing round Series A totalling $38m incl co-lead investor OMX Ventures 2023-12-12
Freya Biosciences–PERSON: investment, 202312 financing round Series A totalling $38m incl co-investor Mike Jafar Family Office 2023-12-12
Freya Biosciences–SEVERAL: investment, 202312 financing round Series A $38m led by Sofinnova Partners + OMX Ventures 2023-12-12
Freya Biosciences–Sofinnova: investment, 202312 financing round Series A totalling $38m incl co-lead investor Sofinnova Partners 2023-12-12
Shinobi Therapeutics–EQT: investment, 202312 financing round Series A totalling $51m incl co-lead investor EQT Life Sciences 2023-12-12
Shinobi Therapeutics–SEVERAL: investment, 202312 financing round Series A $51m led by EQT LS + F-Prime Capital + Eight Roads Ventures Japan 2023-12-12
Oblique Therapeutics–AAX Biotech: antibody development, 202311– collab developm of antibodies for pain using Seqitope to characterise candidates 2023-11-28
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital 2023-11-15
Nouscom–EQT: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor EQT Life Sciences 2023-11-14
VectorY–EQT: investment, 202311 financing round Series A totalling €129m incl new + co-lead investor EQT Life Sciences Dementia Fund 2023-11-13
VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund 2023-11-13
AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004 2023-11-09
Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion 2023-11-07
Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures 2023-11-07
Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC 2023-11-01
AstraZeneca–Nanoform: drug delivery technology, 202310– license ww to Starmap Online 2023-10-23
FarmInsect–Sandwater: investment, 202310 financing round Series A totalling €8m incl new + lead investor Sandwater 2023-10-23
FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater 2023-10-23
Olink–Thermo Fisher: investment, 202310– acquisition cash tender offer $3.1b at $26/share by Thermo Fisher 2023-10-17
1 2 3 4 5 6 7 8 9 10  next pagenext page



Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture biomindz Brand LSE Mainz Place to Biotech 650x300px

» top